Tvardi Therapeutics (NASDAQ:TVRD) Now Covered by Analysts at Chardan Capital

Equities research analysts at Chardan Capital began coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating on the stock.

Several other research analysts also recently commented on the stock. Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, July 8th. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. BTIG Research cut their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a report on Wednesday, July 8th. Finally, Wall Street Zen cut shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tvardi Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $9.40.

Tvardi Therapeutics Trading Down 4.0%

TVRD opened at $0.97 on Tuesday. The stock has a market capitalization of $12.94 million, a P/E ratio of -0.35 and a beta of 0.38. The stock has a 50-day moving average price of $1.55 and a 200-day moving average price of $2.46. Tvardi Therapeutics has a 12-month low of $0.93 and a 12-month high of $6.43.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, equities research analysts predict that Tvardi Therapeutics will post -2.35 EPS for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of large investors have recently bought and sold shares of TVRD. BlackRock Inc. bought a new stake in Tvardi Therapeutics in the second quarter valued at approximately $181,000. Susquehanna International Group LLP bought a new position in shares of Tvardi Therapeutics in the second quarter worth approximately $63,000. Finally, GSA Capital Partners LLP bought a new position in shares of Tvardi Therapeutics in the second quarter worth approximately $34,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.